Pfizer, BioNTech release preliminary data on Covid-19 vaccine candidate
The data were posted on a preprint server and are currently undergoing peer review for potential publication. The companies anticipate starting a Phase IIb/III study for the vaccine, BNT162b1, this month, pending regulatory approval.